| P2093 | author name string | Shayan Shirazian | |
| | Hector Alvarado Verduzco | |
| P2860 | cites work | Therapeutic effect of topical gamma-linolenic acid on refractory uremic pruritus | Q79782064 |
| | Uraemic xerosis | Q80490157 |
| | Gabapentin: a promising drug for the treatment of uremic pruritus | Q80750289 |
| | Effect of skin care with an emollient containing a high water content on mild uremic pruritus | Q81303696 |
| | Treatment of uremic pruritus with narrowband ultraviolet B phototherapy: an open pilot study | Q81867634 |
| | Understanding symptoms in patients with advanced chronic kidney disease managed without dialysis: use of a short patient-completed assessment tool | Q82996977 |
| | How do nephrologists in haemodialysis units consider the symptom of itch? Results of a survey in Germany | Q83207289 |
| | Interleukin-2 serum levels are elevated in patients with uremic pruritus: a novel finding with practical implications | Q83524661 |
| | Efficacy of topical cromolyn sodium 4% on pruritus in uremic nephrogenic patients: a randomized double-blind study in 60 patients | Q84456276 |
| | Prevalence of chronic kidney disease-associated pruritus among adult dialysis patients: A meta-analysis of cross-sectional studies | Q88794993 |
| | A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus | Q91188687 |
| | Charcoal for the management of pruritus and uremic toxins in patients with chronic kidney disease | Q91277904 |
| | Gabapentin for uremic pruritus: a systematic review of randomized controlled trials | Q91499850 |
| | Inhibition of natriuretic peptide receptor 1 reduces itch in mice | Q91775876 |
| | Reasons for Underreporting of Uremic Pruritus in People With Chronic Kidney Disease: A Qualitative Study | Q92953880 |
| | Pruritus and Patient Reported Outcomes in Non-Dialysis CKD | Q93038694 |
| | Uremic pruritus: skin divalent ion content and response to ultraviolet phototherapy | Q93564838 |
| | Gabapentin for uremic pruritus in hemodialysis patients: a qualitative systematic review | Q26750002 |
| | Why we scratch an itch: the molecules, cells and circuits of itch | Q26865093 |
| | Assessment of severity and burden of pruritus | Q28066990 |
| | Cromolyn sodium: a potential therapy for uremic pruritus? | Q30440242 |
| | The Dialysis Outcomes and Practice Patterns Study (DOPPS): design, data elements, and methodology | Q30970415 |
| | Opioids and the skin--where do we stand? | Q33347020 |
| | Acupuncture for treating uremic pruritus in patients with end-stage renal disease: a systematic review | Q33686591 |
| | Systematic review of topical capsaicin in the treatment of pruritus | Q33762584 |
| | The 5-D itch scale: a new measure of pruritus. | Q33871967 |
| | A longitudinal study of uremic pruritus in hemodialysis patients | Q34075489 |
| | Development of the kidney disease quality of life (KDQOL) instrument. | Q34317595 |
| | Sericin cream reduces pruritus in hemodialysis patients: a randomized, double-blind, placebo-controlled experimental study | Q34420464 |
| | Randomized, double-blind study with glycerol and paraffin in uremic xerosis. | Q34751820 |
| | Uremic pruritus, dialysis adequacy, and metabolic profiles in hemodialysis patients: a prospective 5-year cohort study | Q34937539 |
| | The Skindex instruments to measure the effects of skin disease on quality of life | Q35714588 |
| | Uremic pruritus: a review. | Q36271104 |
| | A Comparison of Uremic Pruritus in Patients Receiving Peritoneal Dialysis and Hemodialysis | Q36664020 |
| | Comparison of Gabapentin and Ketotifen in Treatment of Uremic Pruritus in Hemodialysis Patients. | Q36697791 |
| | Comparison of uremic pruritus between patients undergoing hemodialysis and peritoneal dialysis | Q37034706 |
| | Clinical characteristics and outcomes of end-stage renal disease patients with self-reported pruritus symptoms | Q37413002 |
| | Targeted treatment of pruritus: a look into the future | Q37827172 |
| | The role of ondansetron in the management of cholestatic or uremic pruritus--a systematic review | Q38021147 |
| | Understanding the pathophysiology of itch | Q38095597 |
| | Uremic pruritus. | Q38176751 |
| | Targeting Itch with Ligands Selective for κ Opioid Receptors | Q38415148 |
| | Nalfurafine hydrochloride to treat pruritus: a review | Q38501089 |
| | Pruritus in Kidney Disease | Q38583951 |
| | The Worst Itch Numeric Rating Scale for patients with moderate to severe plaque psoriasis or psoriatic arthritis | Q39074683 |
| | Chronic Pruritus: Current and Emerging Treatment Options. | Q39156148 |
| | Pruritus in hemodialysis patients: Results from the Japanese Dialysis Outcomes and Practice Patterns Study (JDOPPS). | Q39207931 |
| | The effect of ergocalciferol on uremic pruritus severity: a randomized controlled trial | Q39231261 |
| | Zinc sulfate for relief of pruritus in patients on maintenance hemodialysis | Q39250061 |
| | Effects of turmeric on uremic pruritus in end stage renal disease patients: a double-blind randomized clinical trial | Q39259414 |
| | Effect of oral granisetron in uremic pruritus | Q39332055 |
| | Pruritus in haemodialysis patients: International results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). | Q39346154 |
| | A randomized, placebo-controlled, double-blind trial of ondansetron in renal itch | Q39397866 |
| | Clinical features of pruritus among patients undergoing maintenance hemodialysis | Q39564303 |
| | Relief of idiopathic generalized pruritus in dialysis patients treated with activated oral charcoal | Q39570637 |
| | Relief of uremic pruritus with ultraviolet phototherapy | Q39581625 |
| | Depressive symptoms predict the future risk of severe pruritus in haemodialysis patients: Japan Dialysis Outcomes and Practice Patterns Study | Q39993959 |
| | Epidemiology and determinants of pruritus in pre-dialysis chronic kidney disease patients | Q40112220 |
| | Prevalence and Associated Factors of Uraemic Pruritus in Continuous Ambulatory Peritoneal Dialysis Patients | Q41123300 |
| | Elevated Plasma Histamine in Chronic Uremia Effects of Ketotifen on Pruritus | Q41151097 |
| | Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial | Q41673941 |
| | Topical capsaicin therapy in humans with hemodialysis-related pruritus | Q42167689 |
| | Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. | Q42495512 |
| | Efficacy of topical hydrating and emollient lotion containing 10% urea ISDIN® plus dexpanthenol (Ureadin Rx 10) in the treatment of skin xerosis and pruritus in hemodialyzed patients: an open prospective pilot trial. | Q42618083 |
| | B-type (brain) natriuretic peptide and pruritus in hemodialysis patients | Q42851379 |
| | Evaluating the association between alterations in mineral metabolism and pruritus in hemodialysis patients | Q43958355 |
| | Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study | Q44030301 |
| | Intractable pruritus as a manifestation of secondary hyperparathyroidism in uremia. Disappearance of itching after subtotal parathyroidectomy | Q44209697 |
| | Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies | Q44350825 |
| | Antipruritic effects of two different 5-HT3 receptor antagonists and an antihistamine in haemodialysis patients | Q44893818 |
| | A prospective proof of concept study of the efficacy of tacrolimus ointment on uraemic pruritus (UP) in patients on chronic dialysis therapy | Q44901262 |
| | A comparative study on the effects of naltrexone and loratadine on uremic pruritus | Q44922690 |
| | Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial | Q45170301 |
| | Gabapentin and uremic pruritus in hemodialysis patients | Q46124053 |
| | A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients | Q46343813 |
| | Uremic pruritus is associated with higher kt/V and serum calcium concentration. | Q46347215 |
| | Lack of efficacy of tacrolimus ointment 0.1% for treatment of hemodialysis-related pruritus: a randomized, double-blind, vehicle-controlled study | Q46371191 |
| | Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: a preliminary study | Q46832897 |
| | Baseline serum levels of mast cell tryptase are raised in hemodialysis patients and associated with severity of pruritus | Q46864210 |
| | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Nalbuphine ER Tablets for Uremic Pruritus | Q47652784 |
| | International Comparisons of Prevalence, Awareness, and Treatment of Pruritus in People on Hemodialysis | Q47688794 |
| | Comparison of pregabalin with ondansetron in treatment of uraemic pruritus in dialysis patients: a prospective, randomized, double-blind study | Q48069006 |
| | Comparison of the efficacy and safety of zinc sulfate vs. placebo in the treatment of pruritus of hemodialytic patients: a pilot randomized, triple-blind study | Q48106996 |
| | Narrowband ultraviolet B phototherapy for patients with refractory uraemic pruritus: a randomized controlled trial | Q48298203 |
| | Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study | Q48381465 |
| | The impact of pruritus on the quality of life of patients undergoing dialysis: a single centre cohort study. | Q48402804 |
| | Symptoms in advanced renal disease: a cross-sectional survey of symptom prevalence in stage 5 chronic kidney disease managed without dialysis | Q48447761 |
| | Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients | Q48502316 |
| | Acupuncture in haemodialysis patients at the Quchi (LI11) acupoint for refractory uraemic pruritus | Q48546922 |
| | Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study. | Q48729261 |
| | Cholestyramine in uraemic pruritus | Q50318025 |
| | Pruritus and skin hydration during dialysis. | Q50992438 |
| | Itch Severity Scale: a self-report instrument for the measurement of pruritus severity. | Q51907501 |
| | Uraemic pruritus: relief of itching by gabapentin and pregabalin. | Q52639674 |
| | The role of micro-inflammation in the pathogenesis of uraemic pruritus in haemodialysis patients. | Q53651902 |
| | Longitudinal predictors of uremic pruritus. | Q54633073 |
| | Hypervitaminosis A accompanying advanced chronic renal failure | Q55397794 |
| | [Pruritus in chronic uremic patients in periodic hemodialysis. Treatment with terfenadine (an antagonist of histamine H1 receptors)] | Q61685087 |
| | Assessment of Pruritus Intensity: Prospective Study on Validity and Reliability of the Visual Analogue Scale, Numerical Rating Scale and Verbal Rating Scale in 471 Patients with Chronic Pruritus | Q62073509 |
| | Dialysis efficacy and itching in renal failure | Q67583011 |
| | Uremic pruritus in patients on hemodialysis or continuous ambulatory peritoneal dialysis (CAPD). The role of plasma histamine and skin mast cells | Q67674262 |
| | Dermatologic evaluation of pruritus in patients on hemodialysis | Q69032387 |
| | Intraepidermal neuron-specific enolase (NSE)-immunoreactive nerve fibres: evidence for sprouting in uremic patients on maintenance hemodialysis | Q69504333 |
| | Naloxone in the treatment of uremic pruritus: a case history | Q70584394 |
| | Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness | Q71695967 |
| | Randomised crossover trial of naltrexone in uraemic pruritus | Q71849293 |
| | Disappearance of "uremic" itching after subtotal parathyroidectomy | Q72090729 |
| | Optimal dialysis improves uremic pruritus | Q72582674 |
| | Effects of azelastin on pruritus and plasma histamine levels in hemodialysis patients | Q72613687 |
| | Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial | Q72742589 |
| | Uremic pruritus: roles of parathyroid hormone and substance P | Q73202115 |
| | A study on pruritus after parathyroidectomy for secondary hyperparathyroidism | Q73333523 |
| | Short-term efficacy of tacrolimus ointment in severe uremic pruritus | Q73535507 |
| | Is pruritus in chronic uremic patients related to peripheral somatic and autonomic neuropathy? Study by R-R interval variation test (RRIV) and by sympathetic skin response (SSR) | Q74317479 |
| | Effects of oral supplementation with evening primrose oil for six weeks on plasma essential fatty acids and uremic skin symptoms in hemodialysis patients | Q77954395 |
| P433 | issue | 9 | |
| P304 | page(s) | 1387-1402 | |
| P577 | publication date | 2020-05-08 | |
| P1433 | published in | KI reports | Q27727507 |
| P1476 | title | CKD-Associated Pruritus: New Insights Into Diagnosis, Pathogenesis, and Management | |
| P478 | volume | 5 | |